The CDA Foundation. Polaris Dashboard 2024. https://cdafound.org/polaris/dashboard/.

Hui RW, Mak LY, Seto WK, Yuen MF. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opin Emerg Drugs. 2022;27(2):127–140

Article  CAS  PubMed  Google Scholar 

Ghany MG, Buti M, Lampertico P, Lee HM. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. Hepatology. 2023;78(5):1654–1673

Article  PubMed  Google Scholar 

Mak LY, Seto WK, Hui RW, Fung J, Wong DK, Lai CL, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepatitis. 2019;26(7):818–827

Article  CAS  Google Scholar 

Mak LY, Hui RW, Chung MSH, Wong DK, Fung J, Seto WK, et al. Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum enhanced liver fibrosis test. J Gastroenterol Hepatol. 2024;39:2826–2834

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hui RW, Mak LY, Cheung TT, Lee VH, Seto WK, Yuen MF. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clin Mol Hepatol. 2022;29(2):217–229

Article  PubMed  PubMed Central  Google Scholar 

Hui RW, Mak LY, Seto WK, Yuen MF, Fung J. Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy. Expert Rev Gastroenterol Hepatol. 2023;17(5):443–450

Article  CAS  PubMed  Google Scholar 

Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis. 2011;204(3):415–418

Article  CAS  PubMed  Google Scholar 

Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58(4):676–683

Article  CAS  PubMed  Google Scholar 

Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156(3):635–646

Article  CAS  PubMed  Google Scholar 

Hui RW, Mak LY, Cheung KS, Fung J, Seto WK, Yuen MF. Novel combination strategies with investigational agents for functional cure of chronic hepatitis B infection. Curr Hepat Rep. 2022;21(4):59–67

Article  Google Scholar 

Yuen MF, Lai CL. Hepatitis B in 2014: HBV research moves forward–receptors and reactivation. Nat Rev Gastroenterol Hepatol. 2015;12(2):70–72

Article  PubMed  Google Scholar 

Park JH, Iwamoto M, Yun JH, Uchikubo-Kamo T, Son D, Jin Z, et al. Structural insights into the HBV receptor and bile acid transporter NTCP. Nature. 2022;606(7916):1027–1031

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389(1):22–32

Article  CAS  PubMed  Google Scholar 

Mak LY, Hui RW, Fung J, Seto WK, Yuen MF. The role of different viral biomarkers on the management of chronic hepatitis B. Clin Mol Hepatol. 2023;29(2):263–276

Article  PubMed  PubMed Central  Google Scholar 

Erken R, Andre P, Roy E, Kootstra N, Barzic N, Girma H, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study. J Viral Hepat. 2021;28(12):1690–1698

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hui RW, Mak LY, Seto WK, Yuen MF. RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Mol Hepatol. 2022;28:408–424

Article  PubMed  PubMed Central  Google Scholar 

Michler T, Kosinska AD, Festag J, Bunse T, Su J, Ringelhan M, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology. 2020;158(6):1762–75.e9

Article  CAS  PubMed  Google Scholar 

Hui RW, Mak LY, Seto WK, Yuen MF. Investigational RNA interference agents for hepatitis B. BioDrugs. 2024;39:21–32

Article  PubMed  PubMed Central  Google Scholar 

Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387(21):1957–1968

Article  CAS  PubMed  Google Scholar 

Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol. 2022;77(5):1287–1298

Article  CAS  PubMed  Google Scholar 

Gane E, Lim YS, Kim JB, Jadhav V, Shen L, Bakardjiev AI, et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials. J Hepatol. 2023;79(4):924–932

Article  CAS  PubMed  Google Scholar 

Yuen MF, Holmes J, Strasser SI, Leerapun A, Sukeepaisarnjaroen W, Tangkijvanich P, et al., editors. 48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy. Global Hepatitis Summit; 2023; Paris, France.

Seto WK, Liang Z, Gan LM, Fu J, Yuen MF. Safety and antiviral activity of RBD1016, a RNAi therapeutic, in Chinese subjects with chronic hepatitis B virus (HBV) infection. J Hepatol. 2023;78(S1):S1152

Article  Google Scholar 

Gane EJ, Kim W, Lim TH, Tangkijvanich P, Yoon JH, Sievert W, et al. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection. J Hepatol. 2023;79(5):1139–1149

Article  CAS  PubMed  Google Scholar 

Hui RW, Mak LY, Seto WK, Yuen MF. Role of core/capsid inhibitors in functional cure strategies for chronic hepatitis B. Curr Hepat Rep. 2020;19(3):293–301

Article  Google Scholar 

Mak LY, Hui RW, Seto WK, Yuen MF. Novel drug development in chronic hepatitis B infection: capsid assembly modulators and nucleic acid polymers. Clin Liver Dis. 2023;27(4):877–893

Article  PubMed  Google Scholar 

Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K, et al. Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/AAC.00560-17

Article  PubMed  PubMed Central  Google Scholar 

Yuen MF, Gane E, Schwabe C, Jucov A, Haceatrean A, Wu M, et al. Monotherapy with the capsid assembly modulator, ALG-000184, results in high viral suppression rates in untreated HBeAg+ and HBeAg- subjects with chronic heaptitis B infection. Hepatology. 2024;80:S166–S167

Google Scholar 

Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180–2194

Article  CAS  PubMed  Google Scholar 

Zheng P, Dou Y, Wang Q. Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity. Front Cell Infect Microbiol. 2023;13:1206720

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology. 2016;150(3):684–95.e5

Article  CAS  PubMed  Google Scholar 

Mifsud E, Tan A, Jackson D. TLR agonists as modulators of the innate immune response and their potential as agents against infectious disease. Front Immunol. 2014. https://doi.org/10.3389/fimmu.2014.00079

Article